Welcome to our dedicated page for KESTRA MEDICAL TECHNOLOGIES, LTD. SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KESTRA MEDICAL TECHNOLOGIES, LTD.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KESTRA MEDICAL TECHNOLOGIES, LTD.'s regulatory disclosures and financial reporting.
KESTRA MEDICAL TECHNOLOGIES, LTD. reports a planned sale of 13,017 shares of common stock through Merrill Lynch on July 31, 2026, listed on NASDAQ. These shares were acquired on July 17, 2026 as a performance stock issuance granted under the issuer’s equity compensation plan. Over the prior three months, reporting person Brian Webster sold multiple blocks of common shares, including 15,000-share transactions on April 15, May 15, June 15, and July 15, 2026, and additional sales of 7,857 and 8,948 shares on July 30 and July 31, 2026, respectively, each with stated aggregate sale values.
KESTRA MEDICAL TECHNOLOGIES, LTD. insider Alfred J Ford has filed to sell common stock under Rule 144. The planned sale covers 8,681 shares of common stock through Merrill Lynch, with an aggregate market value of $196,284.58, and is expected on July 31, 2026 on NASDAQ.
The shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. Over the past three months, Ford has already sold 5,936 shares for an aggregate sale price of $135,120.73.
Vaseem Mahboob filed a notice of intent to sell common stock of Kestra Medical Technologies, Ltd. under Rule 144, with sales to be executed through Merrill Lynch on or after July 31, 2026 on the NASDAQ market.
The common shares were originally acquired through the vesting of performance share unit awards on July 17, 2026 as part of the issuer’s equity compensation plan. The filing also notes a prior sale during the last three months of 3,980 common shares for $90,560.62. The issuer reports 58,602,497 common shares outstanding in connection with this notice.
Kestra Medical Technologies, Ltd. (KMTS) has a notice from insider Traci Umberger indicating an intent to sell up to 8,752 shares of common stock through Merrill Lynch on or after July 31, 2026 on NASDAQ. These shares are tied to the July 17, 2026 vesting of performance share unit awards, granted as part of the company’s equity compensation program.
The filing also reports that Umberger sold 5,887 shares of common stock on July 30, 2026 for 133,892.22 during the prior three months, providing recent trading history associated with this insider’s holdings.
Kestra Medical Technologies, Ltd. has a notice of proposed sale of common stock by insider Timothy Moran under Rule 144. The filing lists up to 8,759 shares of common stock to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $198,000.29 as of July 31, 2026. These shares relate to the vesting of performance share unit awards granted under the issuer’s equity compensation plan on July 17, 2026. The filing also reports that on July 30, 2026, Moran sold 4,117 shares of common stock for $93,758.64 within the past three months.
Kestra Medical Technologies, Ltd. (KMTS) reports a planned sale of up to 8,948 common shares through Merrill Lynch, to be sold on or after July 31, 2026 on NASDAQ, with an approximate aggregate market value of $202,259.77. These shares were issued on July 17, 2026 as a performance stock issuance granted under the issuer’s equity compensation plan. The filing also lists recent sales by Brian Webster over the past three months, including 15,000 common shares on each of April 15, May 15, June 15, and July 15, 2026, and an additional 7,857 shares on July 30, 2026, for stated proceeds on each date.
Kestra Medical Technologies, Ltd. has a proposed sale of 4,117 shares of its common stock through Merrill Lynch on NASDAQ, dated 07/30/2026. The shares relate to performance share unit awards that vested on 07/17/2026 and were granted under the issuer’s equity compensation plan.
Kestra Medical Technologies, Ltd. reports a planned sale of 7,857 shares of common stock through Merrill Lynch on July 30, 2026. These shares relate to a performance stock issuance dated July 17, 2026, granted under an issuer equity compensation plan. Recent sales over the past three months include four transactions of 15,000 common shares each by Brian Webster.
Kestra Medical Technologies, Ltd. filed to permit the sale of up to 5,887 shares of common stock through Merrill Lynch on or about July 30, 2026 on NASDAQ. These shares relate to the vesting of performance share unit awards on July 17, 2026, originally granted as part of issuer equity compensation.
Kestra Medical Technologies, Ltd. has a planned resale of common stock by a security holder. The notice covers 5,936 shares of common stock to be sold through Merrill Lynch on or after July 30, 2026 on NASDAQ. These shares relate to the vesting of performance share unit awards on July 17, 2026, which were granted under the issuer’s equity compensation plan.